Companies Deepen Therapeutic Focus: The EY Firepower Report
M&A Opportunities Likely In 2020 In Cell And Gene Therapy And In Immune-Oncology.
Growth gaps and a desire to concentrate on a small number of therapeutic areas are expected to continue to drive M&A in 2020, but thought needs to be given to investing in data-driven and digital technologies, a new EY report says.
